ArticlePloS one2022

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

Natalia Vargas-Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.